Amphotericin B lipid complex overdosage

Revision as of 06:13, 10 January 2014 by Ahmed Zaghw (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Amphotericin B lipid complex
ABELCET® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Overdosage

Amphotericin B desoxycholate overdose has been reported to result in cardio-respiratory arrest. Fifteen patients have been reported to have received one or more doses of ABELCET® between 7-13 mg/kg. None of these patients had a serious acute reaction to ABELCET®.

If an overdose is suspected:

  1. Discontinue therapy
  2. Monitor the patient’s clinical status
  3. Administer supportive therapy as required. ABELCET® is not hemodialyzable.[1]

References

  1. "ABELCET (AMPHOTERICIN B, DIMYRISTOYLPHOSPHATIDYLCHOLINE, DL- AND DIMYRISTOYLPHOSPHATIDYLGLYCEROL, DL-) INJECTION [SIGMA-TAU PHARMACEUTICALS, INC.]".

Adapted from the FDA Package Insert.